Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Forckenbeckstraße 6, 52074, Aachen, Germany.
Institute for Molecular Biotechnology, Worringerweg 1, RWTH Aachen University, 52074, Aachen, Germany.
Sci Rep. 2017 Sep 20;7(1):11991. doi: 10.1038/s41598-017-11819-4.
Pichia pastoris is a simple and powerful expression platform that has the ability to produce a wide variety of recombinant proteins, ranging from simple peptides to complex membrane proteins. A well-established fermentation strategy is available comprising three main phases: a batch phase, followed by a glycerol fed-batch phase that increases cell density, and finally an induction phase for product expression using methanol as the inducer. We previously used this three-phase strategy at the 15-L scale to express three different AMA1-DiCo-based malaria vaccine candidates to develop a vaccine cocktail. For two candidates, we switched to a two-phase strategy lacking the intermediate glycerol fed-batch phase. The new strategy not only provided a more convenient process flow but also achieved 1.5-fold and 2.5-fold higher space-time yields for the two candidates, respectively, and simultaneously reduced the final cell mass by a factor of 1.3, thus simplifying solid-liquid separation. This strategy also reduced the quantity of host cell proteins that remained to be separated from the two vaccine candidates (by 34% and 13%, respectively), thus reducing the effort required in the subsequent purification steps. Taken together, our new fermentation strategy increased the overall fermentation performance for the production of two different AMA1-DiCo-based vaccine candidates.
毕赤酵母是一种简单而强大的表达平台,能够生产各种重组蛋白,从简单的肽到复杂的膜蛋白。目前已经建立了一种成熟的发酵策略,包括三个主要阶段:一个分批阶段,接着是一个甘油补料分批阶段,该阶段可以提高细胞密度,最后是一个使用甲醇作为诱导剂的产物表达诱导阶段。我们之前在 15-L 规模上使用这种三阶段策略来表达三种不同的基于 AMA1-DiCo 的疟疾疫苗候选物,以开发疫苗鸡尾酒。对于两个候选物,我们转而采用缺乏中间甘油补料分批阶段的两阶段策略。新策略不仅提供了更方便的工艺流程,而且分别使这两个候选物的时空产率提高了 1.5 倍和 2.5 倍,同时将最终细胞质量降低了 1.3 倍,从而简化了固液分离。该策略还减少了与两种疫苗候选物分离的宿主细胞蛋白的数量(分别减少了 34%和 13%),从而减少了后续纯化步骤所需的工作量。总之,我们的新发酵策略提高了两种不同 AMA1-DiCo 疫苗候选物生产的整体发酵性能。